𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease

✍ Scribed by Ariel Gordin; David J. Brooks

Publisher
Springer
Year
2007
Tongue
English
Weight
420 KB
Volume
254
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Simultaneous MAO-B and COMT inhibition i
Simultaneous MAO-B and COMT inhibition in L-dopa-treated patients with parkinson's disease
✍ Dr. Jukka Lyytinen; Seppo Kaakkola; Sirpa Ahtila; Päivi Tuomainen; Heikki Terävä 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 801 KB

## Abstract The effect of selegiline (L‐deprenyl) on plasma catecholamines, clinical response, and drug tolerability was studied in 13 patients with Parkinson's disease (PD) treated with L‐Dopa/benserazide and entacapone, a peripheral catechol‐__O__‐methyltransferase (COMT) inhibitor, in a placebo‐

Clinical and pharmacological differences
Clinical and pharmacological differences in early- versus late-onset Parkinson's disease
✍ G. Gomez Arevalo; R. Jorge; S. Garcia; O. Scipioni; Dr. O. Gershanik 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 796 KB

## Abstract We evaluated whether patients with early‐onset Parkinson's disease (EOPD) have a different clinical profile and pharmacological response than those with late‐onset disease (LOPD). We performed a retrospective analysis and an acute pharmacological challenge with L‐Dopa in 34 EOPD (age at